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Background: Successful transfusion of platelet refractory patients is a challenge. Many poten-
tial  donors are needed to sustain human leukocyte antigen matched-platelet transfusion
programs because of the different types of antigens and the constant needs of these patients.
For a highly mixed population such as the Brazilian population, the pool size required to
provide adequate platelet support is unknown.
Methods: A mathematical model was created to estimate the appropriate size of an unrelated
donor pool to provide human leukocyte antigen-compatible platelet support for a Brazilian
population. A group of 154 hematologic human leukocyte antigen-typed patients was used
as  the potential patient population and a database of 65,500 human leukocyte antigen-typed
bone  marrow registered donors was used as the donor population. Platelet compatibility was
based on the grading system of Duquesnoy.
Results: Using the mathematical model, a pool containing 31,940, 1710 and 321 donors would
be  necessary to match more than 80% of the patients with at least ﬁve completely compatible
(no  cross-reactive group), partial compatible (one cross-reactive group) or less compatible
(two cross-reactive group) donors, respectively.
Conclusion: The phenotypic diversity of the Brazilian population has probably made it more
difﬁculty to ﬁnd completely compatible donors. However, this heterogeneity seems to have
facilitated ﬁnding donors when cross-reactive groups are accepted as proposed by the grad-
ing  system of Duquesnoy. The results of this study may help to establish unrelated human
leukocyte antigen-compatible platelet transfusions, a procedure not routinely performed in
most  Brazilian transfusion services.
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Introduction
Platelet alloimmunization is commonly seen in patients with
hemato-oncological disorders requiring frequent red blood
cell and platelet transfusions1 and may be associated with
refractoriness to platelet transfusions (RPT). There may also
be an association between platelet transfusion failure and
patient survival, which increases the clinical importance of
RPT.2
RPT is deﬁned as inappropriately low platelet count
increments following exposure to antigens after two or
more  (usually consecutive) transfusions and must be deter-
mined by objective data which determine platelet transfusion
outcomes.3 This condition may be caused by immune and
non-immune factors. More  than 80% of RPT cases are related
to non-immune causes. Thus, immune causes occur in less
than 20% of the cases involving alloimmunization against
human leukocyte antigens (HLA) and, to a lesser extent human
platelet antigens (HPA), following exposure after transfusion,
pregnancy, or transplantation. Among the immune causes,
HLA antibodies are responsible for approximately 80–90% of
RPT cases and HPA antibodies for approximately 10–20% of
cases, associated or not with HLA antibodies.4
Providing an adequate post-transfusion platelet count
increment to refractory patients is not an easy task; transfu-
sion of HLA-matched platelets is one possibility.5 However, it is
very difﬁcult to ﬁnd multiple HLA-compatible related donors
for one individual.
The HLA system is highly polymorphic6 and the prob-
ability of ﬁnding identical matches may be around 10% of
donations.7,8 When a full match cannot be found, different
strategies are used to select partially HLA-matched donors.
HLA class I speciﬁcities can be grouped into cross-reactive
groups (CREG), mismatches with antigenic similarity that
result in less allorecognition or immune activation.9 The grad-
ing system described by Duquesnoy et al. in the 1970s10
(Table 1) is deﬁned according to the presence of HLA CREGs
and is still widely used by transfusion services. Although in
some cases, the selection of mismatched donors based on HLA
CREGs may fail to produce adequate increments,11 this strat-
egy can increase the number of potential donors in the same
8donor base.
Pool size calculations can be an essential component for
the rational planning of platelet support programs.12 It is esti-
mated that to provide at least ﬁve completely compatible
Table 1 – Description of the grading system of Duquesnoy.
Grade Description 
A HLA identical – all 4 antigens 
BU Only 3 antigens detected – all identical 
B2U Only 2 antigens detected – both identical 
BX 4 antigens detected – 3 antigens identical and 1 cross-reac
BUX 3 antigens detected – 2 identical and 1 cross-reactive 
B2X 4 antigens detected – 2 antigens identical and 2 cross-reac
C 1 antigen mismatch, out-of-CREG 
D All other ≥2 antigen mismatches 
R: recipient; D: donor; HLA: human leukocyte antigen; –: undetected antiger. 2 0 1 6;3 8(1):1–6
donors for more  than 80% of patients, 500, 1000, and 1500
donors would be needed for the Japanese, European Caucasoid
and North American Caucasoid populations, respectively.13
However, for a highly mixed population such as in Brazil,
which is comprised of European, African and Amerindian
roots,14 the pool size required to provide these patients with
adequate platelet support is unknown.
The unrelated donor pool size that might be necessary
if a center wants to provide patients with unrelated HLA-
compatible platelets was estimated using a random sample
from the Brazilian population. A mathematical model was
created for compatibility analysis and its application was illus-
trated in a population of 154 cancer patients. The ﬁndings of
this study may help to establish the transfusion of unrelated
HLA-compatible platelets, which currently is not a routine pro-
cedure in many  Brazilian centers.
Methods
Study  database,  design  and  setting
A group of 154 HLA-typed patients who were submitted
to bone marrow transplantation or who were candidates
for this procedure at Hospital Israelita Albert Einstein (São
Paulo, Brazil) between January 2006 and December 2009 were
included in this retrospective study to illustrate a possible
patient population.
A database of 65,500 HLA-typed bone marrow donors, regis-
tered in the LIG Laboratório de Imunogenética Ltda, São Paulo,
Brazil was used in this study as the potential donor popula-
tion. This database includes samples from the southeastern
(mainly), southern and northeastern regions of Brazil and rep-
resents a section of the National Registry of Bone Marrow
Donors. According to a Brazilian demographic census, these
regions are related to 80% of the population15 and may rep-
resent a good picture of the HLA phenotype diversity of the
Brazilian population. This study was approved by an Ethics
Committee and the Local Review Committee.
Measures  and  statistical  analysisPatients  and  donors
HLA typing was performed by the polymerase chain reaction
sequence speciﬁc oligonucleotide probe (PCR-SSOP) method
for loci A and B.
R/D HLA typing
R A1 A2 B7 B8
D A1 A2 B7 B8
D A1 – B7 B8
D A1 – B8 –
tive D A1 A24 B7 B8
D A1 A24 – B8
tive D A1 A24 B7 B64
D A1 A32 B7 B8
D A1 A32 B7 B64
ens.
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Table 2 – Examples of the compatibility using the grading system of Duquesnoy.
Recipient Duquesnoy classiﬁcation Number of donors Compatibility type n
1
A  1
CC 10B1U 0
B2U 9
B1X 52
PC  93
B2UX 41
B2X 571 LC 571
2
A 2
CC  159B1U 51
B2U 106
B1X 230
PC  848
B2UX 618
B2X 1565 LC 1565
.
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pCC: complete compatible; PC: partial compatible; LC: less compatible
In order to search the donors to match each of the 154
atients automatically, a mathematical model was generated
sing a Visual Basic computer program.16 Platelet HLA com-
atibility was based on the grading system of Duquesnoy
nd HLA cross-reactive antigens were used as described in
able 1.17,18
Donors for each patient were grouped according to the
ompatibility found deﬁned as completely compatible (CC)
or matches A, B1U, B2U (no CREG present), partially com-
atible (PC) for B1X, B2UX matches (only one CREG present)
nd less compatible (LC) for B2X matches (two CREGs present).
he results obtained of two examples from the mathematical
odel validation process are described in Table 2.
An estimation of the required number of donors forach patient was calculated using binomial distribution with
arameters given by the proportion of compatibility observed
n the donor population. The curves to estimate the donor pool
ize were built according to the percentage of patients with at
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igure 1 – Percentage of patients with at least one or ﬁve comple
latelets from a number of registered donors. Dashed lines repreleast one and ﬁve compatible donors for each simulated pool
size. Details of the mathematical model are available upon
request.
The projection model was applied in order to deﬁne how
large the donor pool should be to provide at least ﬁve CC, ﬁve
PC or ﬁve LC donors for 80% of the patient population, which
was considered an acceptable number of donors for platelet
support during the thrombocytopenic period.
Validation  of  the  mathematical  model
The mathematical model was validated by randomly using
10% (15/154) of the patient group. Two HLA experts selected
compatible donors based on the CREG deﬁnition and manu-
ally grouped them based on the grading system of Duquesnoy
using the ﬁlter tool of the Excel program. The same compat-
ible donors were obtained both by manual selection and by
the mathematical model. During this validation period there
ch
40 000
f donors
50 000 60 000
% of patients with at least 5 CC donor match
tely compatible (CC) human leukocyte antigen matched
sent 95% conﬁdence intervals.
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Figure 2 – Percentage of patients with at least one or ﬁve partially compatible (PC) human leukocyte antigen matched
epreplatelets from a number of registered donors. Dashed lines r
were no errors due to failures of the model, therefore, the
automation tool provided reliable histocompatibility analyses.
ResultsProbability  for  ﬁnding  matched  donors
The compatibility program revealed that of the 154 patients,
141 (91.6%) had at least ﬁve CC in the database of 65,500
LC ma
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Figure 3 – Percentage of patients with at least one or ﬁve less com
from a number of registered donors. Dashed lines represent 95%sent 95% conﬁdence intervals.
registered donors, and all patients (100%) had at least ﬁve PC
and LC donors.
Required  pool  size  to  match  80%  of  the  patient  population
with at  least  one  donorFigures 1–3 show that according to this projection model it is
necessary to have a pool containing 6502, 341 and 65 donors,
respectively to match a minimum of 80% of the patients with
at least one CC, PC or LC donor. More than 65,500 donors would
tch
1500 2000 2500
 donors
% of patients with at least 5 LC donor match
patible (LC) human leukocyte antigen matched platelets
 conﬁdence intervals.
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e necessary to ﬁnd at least one CC donor for all patients (100%
uccess rate).
equired  pool  sizes  to  match  80%  of  the  patient
opulation  with  at  least  ﬁve  donors
ools of 31,940, 1710 and 321 donors would be necessary to
rovide at least ﬁve CC, PC or LC donors to 80% of the patients,
espectively according to the projection model (Figures 1–3).
ools of 23,393 and 2500 donors would be enough to match
00% of the patients with ﬁve PC and LC donors, respectively.
iscussion
he present projection model shows that pools of 31,940,
710 and 321 donors would be necessary to match 80% of the
atients with at least ﬁve CC, PC or LC donors, respectively.
his calculation, based on a different mathematical model,
as already been performed for the Japanese, European Cau-
asoid and North American Caucasoid populations in which
00, 1000, and 1500 donor candidates would be needed to ﬁnd
t least ﬁve LC donors for more  than 80% of each of these
opulations. On the other hand, to ﬁnd at least ﬁve CC, 5000,
8,000 and 25,000 preselected donor candidates would be nec-
ssary for these populations, respectively.13 In another study,
he authors concluded that 1500 platelet donors would be
equired to supply 75% of the patients with eight LC donors
n the North American Caucasoid population. This calcula-
ion would meet the transfusion needs of community donor
latelet apheresis programs in a reference center (Seattle) of
he United States.19
Brazil’s ethnic and genetic heterogeneity, which is related
o the allelic variants present in the ﬁrst populations that
nhabited the country,20 combined with the existence of many
LA polymorphisms, has most likely made it more  difﬁcult to
nd at least one CC, even when a database of 65,500 individ-
als is used. However, this heterogeneity seems to have acted
s a facilitator when cross-reactive antigens are accepted, as
n the grading system of Duquesnoy.
BX or B2X mismatched products have already been
eported as an acceptable match for platelet transfusions
hen the recipients’ lymphocytotoxic antibodies have low
eactivity,21 even though this type of blood product can
ncrease the chances of alloimmunization and make future
ransfusions difﬁcult. This study shows that, for this level
f compatibility, the pool may be feasible and should have
21–1710 donors. However, to provide ﬁve matching CC
onors, a larger number of donors would be needed (31,940).
hese data support the strategy of including any single cross-
eactive antigen while selecting donors, particularly if the
atient to be transfused presents low titers of antibodies and
onsequently a low probability of alloimmunization.
Successful transfusion of patients with platelet refractory
hrombocytopenia is extremely important. However, many
otential donors are needed to sustain HLA-matched platelet
ransfusion programs because of the considerable variety of
LA types and the constant needs of these patients. The
uestion of the required donor pool size should also consider
easibility and costs.12 The latter is one of the reasons whyr. 2 0 1 6;3 8(1):1–6  5
there are no well-established unrelated HLA-matched platelet
transfusion programs in most Brazilian services. Pool size cal-
culations may provide essential data for rational planning of
platelet transfusion support programs and guide institutions
that aim to build a platelet donor registry.
The use of HLA-matched platelets is not the only approach
used to manage alloimmune RPT. Crossmatching and support
with antigen negative platelet units allow rapid selection of
donors, mainly in patients with uncommon HLA types for
whom it might be virtually impossible to ﬁnd HLA-compatible
donors.22–24 Recently, the use of the HLAMatchmaker algo-
rithm has been reported as an emerging concept for the
management of refractory patients.25,26 The combination of
matching compatible antigens and the application of mis-
match acceptability determined by serum screening for HLA
antibodies has offered an effective approach to an HLA-based
platelet transfusion support policy for refractory patients.27,28
The lack of antibody speciﬁcity is a major limitation in this
study as it does not account for the relative frequencies of
certain antibodies in the population.
Although the frequency of immune refractoriness has
declined during the past decade due to the application of
universal leukoreduction of platelet preparations,2,29 RPT is
a complex process and poses a great challenge in the treat-
ment of thrombocytopenic patients. However, universal blood
leukoreduction is not frequent in the transfusion practices
of Brazil and thus RPT is still a difﬁcult nationwide problem.
Knowing how large the donor pool has to be, may help and
stimulate different centers in Brazil to build unrelated platelet
donor panels.
In conclusion, according to the projection model, 31,940
and 321 donors would be necessary to provide at least ﬁve CC
or LC donors, respectively to 80% of the patients in the Brazil-
ian population. Furthermore, 23,393 and 2500 donors would
be enough to match 100% of the patients with ﬁve PC and LC
donors, respectively. On the other hand, the CC pool size to
match 100% of patients is not possible to calculate possibly
because of the great racial miscegenation of Brazilians.
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